

March 22, 2021

To: All Concerned Parties

Company Name: Solasia Pharma K.K.
Representative: Yoshihiro Arai, President & CEO
(Code number: 4597, TSE Mothers Section)
Contact: Toshio Miyashita, CFO, Director
Tel: 81-3-5843-8049

**Solasia's Partner, Isofol Announced iDSMB Recommended to Complete
Global Phase III AGENT Study for arfolitixorin(SP-05) for Market Registration
as Planned with 440 Patients**

Isofol Medical AB (publ) (STO: ISOFOL), Solasia's partner announced that the independent Data Safety and Monitoring Board (iDSMB) has recommended continuation of the global Phase III AGENT study for arfolitixorin(SP-05) with 440 patients.

For more information, please refer to the following URL link to Isofol's website.

<https://isofolmedical.com/isofol-receives-recommendation-from-idsmb-to-complete-the-global-phase-iii-agent-study-for-market-registration-as-planned-with-440-patients/>

###